

Regd. Office :
'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

October 4, 2017

BSE Limited
1st Floor, P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051

Re.: **Press Release**

Dear Sir / Madam,


We enclose herewith a copy of press release dated October 4, 2017 titled "Zydus receives final approval from the USFDA for Desmopressin Nasal Spray Solution USP".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking You,

Yours faithfully,
For, **CADILA HEALTHCARE LIMITED**



UPEN H. SHAH
COMPANY SECRETARY

Encl.: As above

Zydus receives final approval from the USFDA for Desmopressin Nasal Spray Solution USP

Ahmedabad, 04 October 2017

Zydus Cadila has received the final approval from the USFDA to market Desmopressin Nasal Spray Solution USP, 10 mcg/0.1 mL per Spray, 5 mL bottle. It will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.

Desmopressin Nasal Spray is indicated as an antidiuretic replacement therapy in the management of central diabetes insipidus, polyuria (excessive urination) and polydipsia (drinking excessive amounts of fluids) following head trauma or surgery in the pituitary region and nocturia (excessive urination at night).

The group now has more than 160 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
